India's patent laws under pressure: The Lancet special report

September 10, 2012

In a special report in The Lancet, researchers from Queen Mary, University of London (UK) argue that pending cases against India's patent laws threaten public health and misinterpret international intellectual property agreements.

The report, which is published today (Monday), highlights by two , Bayer and , to key provisions of India's Patents Act. Bayer's appeal was heard last week, and the Indian Supreme Court is due to hear Novartis' appeal tomorrow (11th September).

In their report, "India's patent laws under pressure", Peter Roderick, a barrister, and Allyson Pollock, Professor of Public Health Research and Policy, both from the Centre for Primary Care and Public Health at Queen Mary, University of London, say that the Bayer and Novartis cases "are seeking to undermine public health considerations aimed at improving access and therapeutic advantage".

They conclude: "There are many problems facing access to and rational use of medicines in India but the provisions within the country's patent laws, if more extensively and properly applied, should help rather than hinder such access. India's laws and experiences could provide a useful example for low-income and middle-income countries worldwide."

The report outlines the history and details of the two cases, including an analysis of some of the legal background to the actions.

Explore further: India licenses generic copy of patented Bayer drug

More information: "India's patent laws under pressure", by Peter Roderick and Allyson Pollock. The Lancet. dx.doi.org/10.1016/S0140-6736(12)61513-X

Related Stories

India licenses generic copy of patented Bayer drug

March 12, 2012
(AP) -- India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable.

NGOs protest Novartis' Glivec patent quest in India

February 23, 2012
Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.

India patent case threatens cheap drug supply: MSF

September 5, 2011
Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.

Bayer challenges India cancer drug ruling

May 6, 2012
German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

Bayer mulls challenge to India cancer drug ruling

March 13, 2012
Bayer AG said Tuesday it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant.

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.